Research progress of peripheral blood biomarkers in immunotherapy of non-small cell lung cancer
10.3760/cma.j.cn371439-20250110-00028
- VernacularTitle:外周血标志物在非小细胞肺癌免疫治疗中的研究进展
- Author:
Zhiying WANG
1
;
Lijun SHENG
Author Information
1. 山东第一医科大学第三附属医院肿瘤内科五病区，济南 250031
- Keywords:
Carcinoma, non-small-cell lung;
Biomarkers, tumor;
Immunotherapy
- From:
Journal of International Oncology
2025;52(3):180-185
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has achieved relatively satisfactory results in the treatment of non-small cell lung cancer (NSCLC), but not all patients can benefit from immunotherapy. Peripheral blood-based markers are easily accessible and can be monitored dynamically. Peripheral blood tumor cell-related markers (circulating tumor DNA, circulating tumor cells, peripheral blood tumor mutation load, exosomes, etc.), as well as immune and inflammatory markers (T-lymphocyte subpopulations, hematology-associated ratios, C-reactive protein, etc.) have demonstrated great potential in immunotherapy efficacy prediction, prognosis evaluation, and dynamic monitoring.
